OSIMERTINIB-BASED COMBINATION THERAPY FOR EGFR-MUTANT NSCLC WITH BRAIN METASTASES: A CLINICAL CASE IN THE CONTEXT OF THE FLAURA2 STUDY

This article presents a clinical case of treating a female patient with EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases using osimertinib-based combination therapy. Following disease progression after afatinib therapy, third-generation tyrosine kinase inhibitor (osimertinib) targeted therapy was initiated, followed by combination treatment in accordance with the FLAURA2 study protocol. This included osimertinib, chemotherapy (carboplatin + pemetrexed), and bevacizumab. Significant regression of cerebral metastases and disease stabilization were observed. The article discusses practical aspects of applying FLAURA2 data in real-world clinical settings and explores the potential for implementing a personalized approach to oncology, even under budget constraints. The importance of molecular diagnostics and physicians' clinical awareness in making therapeutic decisions is emphasized.